Press Releases

An unprecedented network of centers collaborating to share information and translate these pooled resources into personalized treatments for cancer patients has expanded to 16 institutions with the addition of Roswell Park Comprehensive Cancer Center as a member.

New research led by a team from Roswell Park Comprehensive Cancer Center and published in the journal Nature Methods reports the development of genetically encoded GTP sensors that can rapidly detect changes in GTP levels in living cells.

Chemotherapy-induced peripheral neuropathy, or CIPN, is a common side effect of cancer treatment that causes shooting or burning pain, numbness, tingling and cold sensitivity of the hands and feet for many cancer patients.

While the development of therapies designed to block “checkpoints” within the immune system has been one of the most exciting and noteworthy advances in cancer research in recent years, it’s also been one of the most puzzling, leaving researchers to ask: Why don’t these new therapies work for more patients, and why is their efficacy in controlling cancerous tumors often short-lived? A research team from Roswell Park Comprehensive Cancer Center has shown that at least one answer — and an excellent opportunity for unleashing the full potential of these promising immunotherapies — may lie in the body’s “fight or flight” reaction to stressors and in drugs already widely used to control and temporarily disable this stress response.

Carly’s Club, an organization that raises funds for pediatric cancer research and family support programs at Roswell Park Comprehensive Cancer Center, announced today that it has rebranded as the Courage of Carly Fund.

The first study to report that overall survival was extended for patients receiving lenalidomide as maintenance treatment for multiple myeloma has been completed, with the team’s findings now published online ahead of print in the Journal of Clinical Oncology.

Roswell Park Cancer Institute has been named a 2017–18 Best Hospital for cancer by U.S. News & World Report. The Buffalo, N.Y., comprehensive cancer center was ranked by the news outlet as 33rd among nearly 900 cancer hospitals reviewed nationwide, and was also recognized as high-performing within two other categories: urology and lung cancer surgery.

The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at Roswell Park Comprehensive Cancer Center. The FDA notified MimiVax LLC, a Roswell Park spinoff company, on Aug. 3 that its application for orphan status for SurVaxM as treatment for glioblastoma, a type of brain cancer, had been approved.

Today, 101 cyclists crossed the Niagara Falls finish line to complete the Empire State Ride (ESR), a seven-day, 546-mile adventure across New York State to end cancer. To participate, individuals from as far as California and the Virgin Islands raised more than $500,000 to support cancer research at Roswell Park Comprehensive Cancer Center.